Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
about
The significance of genetics for cholangiocarcinoma developmentRoles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implicationsNCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinomaComputational gene network analysis reveals TNF-induced angiogenesis.Schistosome and liver fluke derived catechol-estrogens and helminth associated cancersInfection with the carcinogenic liver fluke Opisthorchis viverrini modifies intestinal and biliary microbiome.Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3.Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN modelIL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort studySTK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.New Approaches for Studying Alcoholic Liver DiseaseWhy does infection with some helminths cause cancer?Quantitative Study of Cell Invasion Process under Extracellular Stimulation of Cytokine in a Microfluidic Device.Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinomaDeletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice.Knockdown of astrocyte elevated gene-1 inhibits growth through suppression of IL-6 secretion in HepG2 human hepatoma cells.LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA mannerHepatitis B Virus e Antigen Regulates Monocyte Function and Promotes B Lymphocyte Activation.Intrahepatic cholangiocarcinoma: current perspectives.Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinomaGenetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinomaTherapeutic actions of melatonin on gastrointestinal cancer development and progression.Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice.Pathogenesis of Kupffer Cells in Cholestatic Liver Injury.FAK deletion accelerates liver regeneration after two-thirds partial hepatectomy.Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet.High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma.Caspase-2 deficiency accelerates chemically induced liver cancer in mice.Quantitative impedimetric monitoring of cell migration under the stimulation of cytokine or anti-cancer drug in a microfluidic chip.Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.Thiamethoxam induced hepatotoxicity and pro-carcinogenicity in rabbits via motivation of oxidative stress, inflammation, and anti-apoptotic pathway.Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions.Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation.Anti-Metastatic Effects of Antrodan with and without Cisplatin on Lewis Lung Carcinomas in a Mouse Xenograft Model.UEG Week 2015 Poster Presentations
P2860
Q26865749-CAF843AD-6A36-49D2-9226-94BE5F599FA9Q27009016-A0971E18-45EC-4609-86CD-ED9C867EF9C6Q28586911-FF1A1C4A-ACCE-4967-85BD-81FED961C394Q34529983-3D60B567-2317-40F1-B09D-BB5BB25DCB22Q34763466-1B3F33CD-6703-4281-B905-C7F28ABB3995Q34909875-9585C972-757A-4FC7-99A8-A5A87D7D509EQ35051703-B1B19C69-5A76-45EB-9FB6-262E8099562DQ35274375-B1E8EFF5-78D0-4E84-B22C-B4B0A5761820Q35584162-744BE247-17BF-4E57-A3E6-7F540AAA261BQ36266490-8F87FFCB-E8E9-4994-A99F-785106AE92ABQ36288405-F3EAE62F-038C-4B5B-9F91-22412C6AFFD4Q36310498-768C2746-C4E9-431D-9FFC-9210F1EEC37BQ36875903-39BC681C-649E-4FC2-B106-43E3CB310AB9Q37064043-B3554088-46EA-4613-90EE-16EC9670A6EAQ37228773-D0BF6A95-EC01-4E47-AFA0-A1EE61BC6247Q37388677-A87AF866-F073-4F77-AD9C-309C6AA3AB3FQ37390759-63B42008-C1CC-4098-B47C-649082731917Q37571886-451E58FF-528F-4E44-A726-7EBD818933F9Q37669928-7CBBD92B-CF6A-4D20-B12D-3D6D69C8B2FFQ37731958-B67C9D16-82D9-43FF-A13E-DBBEAD1043FCQ38106951-7A1DCAB1-0554-4474-A6A5-1BB3E6CE391DQ38169160-994189C1-E8DE-41F8-A938-1176B8BE361AQ38725977-9E1B6B62-72B8-46DA-96F9-556959A14F51Q38778160-F0228B07-2C9E-42C6-A2E3-3A2F639319F7Q38906942-212DBB06-8F40-4C69-B8E1-ED58B37D60EDQ39346243-9882D93E-6841-450A-A2B8-9C32663F0E89Q40108804-5FEE41C3-35BC-4A1F-8A91-6D77DC8D9ACDQ40917751-0B46CEF8-E201-4004-A35F-69805F211D9AQ40948560-9163B478-7CEF-43EE-B3A5-AE2F325E5E6FQ41636948-0C5F23BF-3E71-4FD4-8E6B-52141BB73940Q41891461-3BE803D1-C964-466E-A643-7CD7ACF5BADDQ42618642-B3C138EF-144B-46B1-82E6-DB2E34476CF0Q46317141-D9598ADB-CA48-412F-92D0-05E2EF1B4E2FQ52725707-12501D79-3B15-4DCC-8806-65AF1DF2866EQ54975275-AEF39EDA-661C-4061-91BC-D78E75C27D63Q54978344-E6A9D560-0B76-4C3D-ABC6-D5822B400020Q56934656-4F3DF83E-B48A-4B75-BBD9-850ED269FE5C
P2860
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@ast
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@en
type
label
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@ast
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@en
prefLabel
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@ast
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@en
P2093
P2860
P1476
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer
@en
P2093
Christopher Johnson
Fanyin Meng
Gianfranco Alpini
Jennifer McCarra
Nathan Hughart
P2860
P356
10.3978/J.ISSN.2224-4778.2011.11.02
P577
2012-04-01T00:00:00Z